[Acellular pertussis vaccine].
Protective, immunogenic, toxic, and sensitizing properties of acellular pertussis vaccine (aPV) developed according to original technology were studied, aPV had marked protective activity which lasted more than 2 years. Sera of mice immunized by aPV also possess protective properties, and they were more prominent than in sera of mice immunized by pertussis bacteria suspension (PS). Immune sera to aPV neutralized cytopathogenic effect of pertussis toxin (PT) on ovarian Chinese hamster cells in 1:250 dilution, whereas neutralizing activity of sera to PS was very low. Level of antibodies to PT was higher in rabbits immunized, according to schedules and dosage recommended for children, by aPV than by PS. High immunogenicity of aPV was proved also by levels of IgG to PT in sera of mice immunized three times by aPV in human dosage. During experiments on mice and guinea pigs aPV had mild toxicity, did not induce autoimmune process, did not have anaphylactogenic properties compared with bacterial suspension characterized by high anaphylactogenic activity. Histamine-sensitizing abilityof aPVwas 40 times lower than that of PS. Assessment of pyrogenic properties of aPV and PS performed on rabbits showed that aPV was 1,000 times less pyrogenic than PS. Obtained results demonstrate high protective and immunogenic properties of domestic acellular pertussis vaccine and its low toxic and sensitizing characteristics.
Zakharova
N S
NS
Britsina
M V
MV
Mertsalova
N U
NU
Bazhanova
I G
IG
Ozeretskovskaia
M N
MN
Zaĭtsev
E M
EM
Poddubikov
A V
AV
Semenov
B F
BF
D000707:Anaphylaxis / Q000139:chemically induced; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000494:pharmacology; D000918:Antibody Specificity; D001327:Autoimmune Diseases / Q000139:chemically induced; D001886:Bordetella pertussis / Q000276:immunology*; D002460:Cell Line; D002678:Chimera; D006224:Cricetinae; D004353:Drug Evaluation, Preclinical; D005260:Female; D005334:Fever / Q000139:chemically induced; D006168:Guinea Pigs; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D009500:Neutralization Tests; D037342:Pertussis Toxin / Q000819:agonists / Q000276:immunology; D010567:Pertussis Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000633:toxicity; D011817:Rabbits; D022282:Vaccines, Acellular / Q000008:administration & dosage / Q000009:adverse effects / Q000633:toxicity; D014917:Whooping Cough / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D010567:Pertussis Vaccine; D022282:Vaccines, Acellular; D037342:Pertussis Toxin